TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
DSGN

Design Therapeutics Inc

Healthcare · Biotechnology · —

12.80$ +2.4% vs. previous close Closing price · As of: Sep 17, 2026

Ownership

Ownership Structure

Who owns Design Therapeutics Inc (DSGN)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 57.8% of the shares are freely tradable; institutional investors hold 62.1%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 62.1%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 31.9%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 57.8%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 11.7%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 63Mio.

Largest Shareholders

Institutions

Institutions DSGN
Name Stake (%) Shares Change (%) Date
SR ONE CAPITAL MANAGEMENT, LP 10.43 6,526,476 +0.0 06/30/2026
Logos Global Management LP 4.79 3,000,000 +53.8 06/30/2026
RA Capital Management, LLC 4.75 2,972,973 +103.4 03/31/2026
Point72 Asset Management, L.P. 4.35 2,722,754 -49.3 03/31/2026
Baker Bros Advisors LP 4.13 2,585,978 +15.8 03/31/2026
BlackRock Inc 3.41 2,133,764 +0.8 03/31/2026
Trails Edge Capital Partners, LP 3.20 2,001,282 +134.9 06/30/2026
Driehaus Capital Management LLC 2.79 1,744,987 +47.9 03/31/2026
Vivo Capital, LLC 2.58 1,612,903 +0.0 06/30/2026
Almitas Capital LLC 2.45 1,530,335 +0.0 03/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?